HPTN 094
A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care

What is HPTN 094?
HPTN 094 is a study that aims to evaluate the effectiveness of a mobile health delivery unit intervention for engaging people who inject drugs in medications for opioid use disorder and HIV care and prevention. The study will be implemented across five sites – Los Angeles, Houston, New York, Philadelphia, and Washington DC. Implementation is expected to begin in spring 2021, with a total duration of approximately 3.5 years. The Los Angeles site is being led by Dr. David Goodman-Meza, Assistant Professor in the Division of Infectious Diseases at the UCLA David Geffen School of Medicine.

Why is the study being done?
The challenge of finding and sustaining HIV care and prevention in the context of untreated opioid use disorder has contributed to multiple HIV outbreaks in the US. The use of a mobile venue that meets out-of-treatment people who inject drugs (PWID) wherever they might be and links them to care systems and/or harm reduction is an innovative intervention that, if efficacious, could be efficiently scaled-up across the US to save lives.

What is the study design?
The study is a two arm, individually randomized, controlled trial. Eligible individuals who consent to participate will be randomized 1:1 to either receive care on the mobile unit with peer navigation (intervention arm), or receive peer navigation to community-based facilities (active control arm). Participants in both arms will receive these services for 26 weeks. The mobile unit will provide medications for opioid use disorder (MOUD), medications for treatment or prevention of HIV, as well as STI and HCV care and pertinent vaccinations. Participants in the active control arm will receive navigation to these services in community-based facilities.

Who is eligible for the study?
Each site is planning to engage approximately 170 participants, with targets of 25% women, 25% participants under 30 years of age, and approximately 90 HIV positive and 80 HIV-negative participants.

Inclusion criteria are:
• 18 to 60 years of age
• Urine test positive for recent opioid use and with evidence of recent injection drug use
• Diagnosed with opioid use disorder per DSM-5
• Willing to start MOUD treatment
• Self-reported sharing injection equipment and/or condomless sex in the last three months with partners of HIV-positive or unknown status

Exclusion criteria are:
• Received MOUD in the 30 days prior to enrollment by self-report
• Co-enrollment in any other interventional study

How can I learn more about HPTN 094 in Los Angeles?
For more information, please contact the Los Angeles HPTN 094 study team at Hptn094@mednet.ucla.edu.